Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 5HIV Infections 4Acquired Immunodeficiency Syndrome 4Sarcoma, Kaposi 3Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Tumor Virus Infections 1Triple Negative Breast Neoplasms 1Solid Cancers 1Sarcoma 1Papillomavirus Infections 1Neoplasm Metastasis 1Breast Neoplasms 1Breast Carcinoma In Situ 1Anus Neoplasms 1Advanced Neoplasm 1Adult Solid Neoplasm 1AIDS-Related Complex 1

Interventions

temsirolimus 2Sirolimus 2Gemcitabine 2ARQ 197 2veliparib 1sargramostim 1pegfilgrastim 1ixabepilone 1cixutumumab 1belinostat 1Vorinostat 1Topotecan 1Tolbutamide 1Taxes 1Sunitinib 1Rifampin 1Paclitaxel 1Omeprazole 1Midazolam 1Ketoconazole 1Isotretinoin 1Irinotecan 1Introns 1Interferon alpha-2 1Hydroxychloroquine 1Erlotinib Hydrochloride 1Epothilones 1Dextromethorphan 1Colony-Stimulating Factors 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adult Solid Neoplasm × Interferon alpha-2 × Clear all
NCT00217373 2015-04-20

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

National Cancer Institute (NCI)

Phase 1 Completed
33 enrolled

Adult Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡